Reaction
Enterocutaneous Fistula reporting signals
As of the last recalculation, Enterocutaneous Fistula appears in 865 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 96.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 51 | 96.7 | 97.1 |
| Adalimumab-Fkjp | 47 | 25.8 | 25.8 |
| Adalimumab-Aaty | 47 | 25.2 | 25.2 |
| Metronidazole | 60 | 24.2 | 24.2 |
| Adalimumab-Adaz | 47 | 22.6 | 22.6 |
| Azathioprine | 75 | 22.3 | 22.4 |
| Infliximab-Dyyb | 26 | 22.0 | 22.1 |
| Bevacizumab | 94 | 20.4 | 20.4 |
| Cholestyramine | 10 | 20.1 | 20.1 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 17 | 20.0 | 20.1 |
| Temozolomide | 17 | 19.8 | 19.8 |
| Vedolizumab | 59 | 17.6 | 17.6 |
| Fluorouracil Cream, 0.5% | 51 | 17.0 | 17.0 |
| Loperamide Hcl | 9 | 17.0 | 17.0 |
| Fluorouracil | 51 | 16.8 | 16.8 |
| Oxaliplatin | 45 | 15.3 | 15.4 |
| Mesalamine | 34 | 15.1 | 15.1 |
| Irinotecan Hydrochloride | 7 | 13.2 | 13.2 |
| Ifosfamide | 11 | 12.5 | 12.5 |
| Ustekinumab | 40 | 9.8 | 9.8 |
| Isotretinoin | 19 | 9.4 | 9.4 |
| Trifluridine And Tipiracil | 4 | 9.0 | 9.0 |
| Pazopanib Hydrochloride | 10 | 9.0 | 9.0 |
| Daptomycin | 3 | 7.8 | 7.9 |
| Cetuximab | 10 | 7.8 | 7.8 |
| Lenvatinib | 10 | 7.4 | 7.4 |